Arivale has raised $36.0M in total across 1 funding round.
Arivale's investors include ARCH Venture Partners, MPM Capital.
Arivale was a scientific wellness company that provided personalized health coaching based on integrated data from genetics, blood, microbiome, and lifestyle to optimize wellness and prevent disease[1][2][3]. Launched in 2014 or 2015, it served consumers seeking proactive health management, charging around $2,000 annually for testing, analysis, and coaching by registered dietitian nutritionists[2][3][4]. Despite raising $49.6M and early traction with over 1,000 customers by mid-2015, Arivale shut down in April 2019 due to high customer acquisition costs, clinician expenses, and scaling challenges in the consumer health market[1][2][4].
Arivale was co-founded by Dr. Leroy Hood, a pioneering geneticist known for developing DNA sequencers and synthesizers at Caltech, founding over 14 biotech firms like Amgen, and advancing systems biology, alongside Clayton Lewis[1][3]. The idea emerged from Hood's vision to apply complex data integration—genome, blood, saliva, gut microbiome, and lifestyle—to create actionable wellness insights, launching services in Seattle's biotech corridor with national expansion plans[1][3]. Early pivotal moments included forming a Scientific Advisory Board of global experts, gaining over 1,000 customers by July 2015, and opening in San Francisco late that year, though it ultimately failed to achieve sustainable growth[3][4].
Arivale stood out in personalized medicine through:
Headquartered at 710 Second Avenue in Seattle's South Lake Union biotech hub, it fostered a mission-driven culture blending scientists, engineers, and coaches[1][2].
Arivale rode the precision wellness and direct-to-consumer genomics trend of the mid-2010s, capitalizing on falling sequencing costs and rising interest in preventive health amid chronic disease burdens[1][3]. Timing aligned with post-23andMe regulatory shifts and early microbiome research, positioning it to pioneer "scientific wellness as a service" in a market shifting from reactive to proactive care[4]. It influenced the ecosystem by validating data-driven coaching—paving the way for competitors like Digbi Health and Bold Health in gut-focused, virtual therapeutics—while highlighting pitfalls like high CAC and unit economics that shaped later category creators' focus on content-led growth and COGS optimization[2][4].
Arivale's shutdown underscores the brutal economics of consumer health innovation, but its blueprint endures in today's AI-enhanced precision platforms. What's next? Its alumni and IP likely fuel spinouts or integrations into firms like those from Hood's Institute for Systems Biology, riding AI-driven multi-omics analysis and telehealth booms. Trends like wearable integration and insurer-backed wellness will amplify similar models, evolving Arivale's bold vision from failed pioneer to foundational cautionary tale in scalable personalization[1][4].
Arivale has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series B in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $36.0M Series B | ARCH Venture Partners, MPM Capital |
